Medical Science Liaison
Revolution Medicines
Medical Science Liaison
Revolution Medicines
Clinical-stage oncology company developing RAS inhibitors
Revolution Medicines is a global, commercial-state oncology company dedicated to discovering, developing and delivering innovative medicines for patients with RAS-addicted cancers. Leveraging its differentiated RAS(ON) tri-complex inhibitor platform, the company is advancing a broad, integrated portfolio of oral RAS(ON) inhibitors designed to directly target the active, cancer-driving state of RAS. Founded on rigorous scientific inquiry and a willingness to challenge long-held assumptions, Revolution Medicines is committed to changing the trajectory of disease for patients with RAS-addicted cancers worldwide.
Our people are united by a shared way of working: follow the science, challenge assumptions, act with urgency and hold ourselves to a high standard of rigor—all in service of patients.
The Opportunity:
We are seeking a highly motivated and experienced professional to join our team as a Medical Science Liaison, France. This role will execute approved field medical plans within an assigned French territory, engage in peer-to-peer scientific dialogue with healthcare professionals that translate into meaningful insights, serve as a therapeutic expert and thought partner to internal teams, liaison between Revolution Medicines and clinical study sites / investigators, and provide support for medical education, advisory boards, and medical congresses.
Medical Science Liaisons (MSLs) are an essential member of the Medical Affairs team who will work as an extension of the Medical Affairs organization. The MSL team will serve as a key liaison between Revolution Medicines and healthcare professionals. Within an assigned geographic territory, the MSL will be responsible for cultivating and strengthening professional relationships with key opinion leaders (KOLs), healthcare providers, and academic centers of excellence involved in various phases of product development. The individual will collaborate with stakeholders within medical affairs and across the organization, including but not limited to Clinical Development, Commercial, Program Management, Clinical Operations, and Compliance teams. The ideal candidate is an effective communicator, driven, detail-oriented, proactive, and a skilled collaborator.
The role is an individual contributor position with no direct line-management accountability.
The MSL contributes field insights and scientific expertise to support the French medical plan but does not own country medical strategy, governance, budget, or team leadership.
Required Skills, Experience and Education:
Develop and maintain strong relationships with KOLs, healthcare professionals, and academic institutions to advance scientific and medical knowledge.
Communicate clinical and scientific data to KOLs and healthcare professionals through presentations, educational programs, and scientific discussions.
Support the synthesis and communicate scientific insights from KOLs to relevant internal teams.
Provide scientific support for medical congresses, advisory boards and other relevant scientific engagements to enhance the visibility of RevMed within the scientific and medical communities.
Establish credibility as a scientific expert and resource for internal stakeholders, providing medical and scientific support for products and therapeutic areas.
Collaborate cross-functionally with medical affairs, clinical development, marketing and other teams to support the development and execution of medical strategies and tactics.
Stay current with scientific literature, emerging research, and competitive landscape.
Adhere to Revolution Medicines Core Values and policies.
Understand the regulatory requirements for customer engagement by field-based employees.
Provide territory-level input to medical planning, launch readiness, and external engagement priorities.
Doctoral degree in scientific or medical discipline.
8+ years experience as an MSL or in a similar role within the pharmaceutical or biotech industry in France.
Strong understanding of clinical research methodologies and drug development processes
Knowledge and experience within the oncology therapeutic area, preferred experience in lung and gastrointestinal cancers.
Excellent verbal and written communication skills.
Proven ability to analyze and synthesize scientific information effectively.
Excellent presentation skills, with the ability to effectively communicate complex scientific data to diverse audiences.
Strong networking skills with proven ability to successfully build and maintain relationships with KOLs and healthcare professionals.
Self-directed and able to thrive in a fast-paced and dynamic environment.
Willingness to travel up to 60% of time.
Revolution Medicines takes protection and security of personal data very seriously and respects your right to privacy while using our website and when contacting us by email or phone. We will only collect, process and use any personal data that you provide to us in accordance with our CCPA Notice and Privacy Policy. For additional information, please contact [email protected].
#LI-JM1 #LI-Remote
We are aware of recent recruitment scams in which individuals or organizations falsely represent themselves as being affiliated with Revolution Medicines. These scams may appear as false job advertisements or unsolicited contacts through communication or chat platforms, email, phone, or text message.
Please note that Revolution Medicines does not extend unsolicited employment offers and will never ask candidates to provide financial information, purchase equipment, or pay fees as part of the hiring process. All legitimate communication from Revolution Medicines will come from an official @revmed.com email address.
If you believe you’ve been contacted by someone impersonating a Revolution Medicines recruiter, please report it to [email protected] so we can share these impersonations with our IT team for tracking and awareness.
Clinical-stage oncology company developing RAS inhibitors
Revolution Medicines develops precision oncology drugs focused on cancers driven by RAS mutations. Its RAS(ON) inhibitors are small molecules that bind the active form of RAS to block cancer signaling, with candidates like Daraxonrasib (RMC-6236), Elironrasib (RMC-6291), and Zoldonrasib (RMC-9805) advancing in global Phase 3 trials. The company funds its research through collaborations, royalties, and upfront funding, and has not yet marketed a product. Its goal is to bring effective RAS-targeted therapies to patients and advance multiple candidates through late-stage trials toward approval, supported by strong cash reserves.
Explore more opportunities at Revolution Medicines